Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 23c

Acrivon Therapeutics, Inc. (NASDAQ: ACRV) reported Q2 EPS of ($0.52), $0.23 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Acrivon Therapeutics, Inc. (ACRV) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• Nvidia said to back $100bn OpenAI data center in Ohio
• Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)